Letter to the Editor| Volume 86, ISSUE 3, P256-308, March 2023

Oseltamivir is protective for in-patient mortality in PCR confirmed influenza B and influenza A(H3N2) infections in an historic cohort of 1,048 patients hospitalised during the 2016-17 and 2017-18  influenza seasons

Published:January 13, 2023DOI:


      Standard course oseltamivir 75mg two times daily for five days was associated with an 82% reduction of odds of in-patient death (OR 0.18 (0.07,0.51)) compared to no oseltamivir treatment (OR 1.0 Reference) in a final multivariable logistic regression model of a retrospective cohort of PCR confirmed influenza B and influenza A (H3N2) infected patients admitted to a large UK teaching hospital in influenza seasons 2016-17 and 2017-18. No difference of protective odds for standard course oseltamivir was observed between influenza B and influenza A (H3N2) nor between influenza seasons. These observations strongly support clinical guidelines for molecular testing for respiratory viruses on admission to hospital and prompt treatment of confirmed seasonal influenza B and A with oseltamivir 75mg twice daily for five days.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Infection
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Poole S
        • Brendish NJ
        • Clark TW
        SARS-CoV-2 has displaced other seasonal respiratory viruses: Results from a prospective cohort study.
        J Infect. 2020; 81: 966-972
        • United Kingdom Health Security Agency
        Weekly Influenza and COVID-19 Surveillance graphs. to.
        week. 2023; 1
      1. United Kingdom Health Security Agency. Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza.

        • Hurt AC
        • Kelly H.
        Debate regarding oseltamivir use for seasonal and pandemic influenza.
        Emerg Infect Dis. 2016; 22: 949-955
        • Reacher M
        • Warne B
        • Reeve L
        • Verlander NQ
        • Jones NK
        • Ranellou K
        • et al.
        Influenza-associated mortality in hospital care: a retrospective cohort study of risk factors and impact of oseltamivir in an English teaching hospital, 2016 to 2017.
        Euro Surveill. 2019; 24